VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 3, 2026

Stock Comparison

reAlpha Tech Corp. vs GSK plc

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

reAlpha Tech Corp.

AIRE · Nasdaq Capital Market

Market cap (USD)$58.1M
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorReal Estate
Industry
CountryUS
Data as of2026-01-02
Moat score
42/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into reAlpha Tech Corp.'s moat claims, evidence, and risks.

View AIRE analysis

GSK plc

GSK · London Stock Exchange

Market cap (USD)$73.6B
Gross margin (TTM)72.4%
Operating margin (TTM)23.5%
Net margin (TTM)17.1%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryGB
Data as of2025-12-28
Moat score
62/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into GSK plc's moat claims, evidence, and risks.

View GSK analysis

Comparison highlights

  • Moat score gap: GSK plc leads (62 / 100 vs 42 / 100 for reAlpha Tech Corp.).
  • Segment focus: reAlpha Tech Corp. has 2 segments (83.5% in Homebuying Platform & Transaction Services); GSK plc has 3 segments (37.6% in Specialty Medicines).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Strong.
  • Moat breadth: reAlpha Tech Corp. has 4 moat types across 2 domains; GSK plc has 4 across 3.

Primary market context

reAlpha Tech Corp.

Homebuying Platform & Transaction Services

Market

Integrated U.S. residential real estate transaction services platform (brokerage + mortgage + title)

Geography

United States

Customer

Homebuyers

Role

Transaction intermediary / service provider

Revenue share

83.5%

GSK plc

Specialty Medicines

Market

Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)

Geography

Global

Customer

Hospitals, specialist physicians, payers

Role

Innovator & branded manufacturer

Revenue share

37.6%

Side-by-side metrics

reAlpha Tech Corp.
GSK plc
Ticker / Exchange
AIRE - Nasdaq Capital Market
GSK - London Stock Exchange
Market cap (USD)
$58.1M
$73.6B
Gross margin (TTM)
n/a
72.4%
Operating margin (TTM)
n/a
23.5%
Net margin (TTM)
n/a
17.1%
Sector
Real Estate
Healthcare
Industry
n/a
Drug Manufacturers - General
HQ country
US
GB
Primary segment
Homebuying Platform & Transaction Services
Specialty Medicines
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Weak
Strong
Moat score
42 / 100
62 / 100
Moat domains
Demand, Legal
Supply, Legal, Demand
Last update
2026-01-02
2025-12-28

Moat coverage

Shared moat types

Compliance AdvantageSwitching Costs General

reAlpha Tech Corp. strengths

Suite BundlingData Workflow Lockin

GSK plc strengths

Capex Knowhow ScaleIP Choke Point

Segment mix

reAlpha Tech Corp. segments

Full profile >

Homebuying Platform & Transaction Services

Competitive

83.5%

AiChat Conversational AI SaaS

Competitive

16.5%

GSK plc segments

Full profile >

Vaccines

Oligopoly

29.1%

Specialty Medicines

Oligopoly

37.6%

General Medicines

Competitive

33.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.